SINGAPORE, Oct. 27, 2025 — In a significant development, LIFE AI has been selected to participate in the first-ever FastTrack AI Accelerator, Cohort 1. This program, powered by GenAI Fund and accelerated by NVIDIA, is designed to propel promising AI startups toward enterprise integration, scalable influence, and investment readiness.
Inclusion in the ASEAN region’s leading enterprise startup accelerator will enable LIFE AI to advance the healthcare industry with greater AI innovations in a shorter timeframe, providing the company with:
- Access to GPU capabilities, technical assistance from NVIDIA specialists, and other cloud provider resources
- Enterprise Proof-of-Concept (PoC) opportunities curated through the GenAI Open Invitation Network
- Investment evaluation and funding prospects from GenAI Fund and its partners
Even before its selection as one of six startups to join Cohort 1 from over 300 applicants, LIFE AI has been making considerable progress as an intelligent layer for human health, significantly reducing hurdles for healthcare product development while making the process 10 times faster and 10 times more cost-effective.
The company, founded by former Google engineering leader Dr. Tuan Cao, along with other engineers and scientists from Cornell University, UC Berkeley, and UCSF, already supports precision health services for over 100,000 paid users across seven countries, including the U.S., Korea, Hong Kong, Singapore, Indonesia, Thailand, and Vietnam.
LIFE AI collaborates with over 100 corporate and institutional partners, including research partnerships with scientists from Stanford, Cornell, and UCSF, and an extensive hospital network across Asia. The company successfully conducted the largest genetic study on autism in Southeast Asia for $10,000, in contrast to an estimated cost of over $1 million, and helped Kalbe Farma, Southeast Asia’s largest pharmaceutical company, launch a personalized stroke prevention product in just six weeks, a process initially planned for 24 months.
This remarkable acceleration, reducing a typical 24-month development cycle to just six weeks, combined with establishing Southeast Asia’s largest genetic study on autism, has served as a testament to LIFE AI’s platform capacity and capabilities, and is a pivotal validation of the company’s value proposition.
LIFE AI will contribute its expanding revenue model and platform offerings to the FastTrack AI Accelerator, transitioning from a traditional model to an AI-first “Model-as-a-Service” strategy, with a strong focus on tangible products, genuine customers, and actual revenue generation.
Being chosen for such a distinguished program marks an exciting achievement in LIFE AI’s journey to scale AI innovation and create significant impact across Southeast Asia. Over the ensuing 12 weeks, the FastTrack AI Accelerator will provide up to $1 million in compute power, technical support from NVIDIA, and practical guidance to accelerate impactful outcomes.
LIFE AI is honored to join this pioneering first Cohort, which will help shape the future of applied AI with innovation, speed, and scale. This journey will be instrumental in advancing our excellence in providing comprehensive solutions for healthcare product development and seamlessly integrating blockchain for ownership, privacy, and transparency.
About LIFE AI
LIFE AI is a Singapore-based company operating a foundational AI platform that enables businesses to launch life science products, such as precision health and drug discovery solutions, from concept to market more quickly and affordably. The company is spearheading the future of health by building the Intelligence Layer of Human Health – a new foundational infrastructure where real individuals, AI computation, and impact-driven models converge within a progressive co-creation ecosystem.
| |
For media inquiries:
Yen Tran
Disclaimer: This content originates from the sponsor. The assertions, perspectives, and opinions presented are exclusively those of the content provider and do not necessarily reflect those of this media platform or its publisher. We do not endorse, validate, or assure the accuracy, completeness, or dependability of any information provided. We do not guarantee any claims or promises made herein. This content is for informational purposes only and should not be construed as financial, investment, or trading advice. Investment in crypto and mining-related ventures carries substantial risks, including the potential for total capital loss. These offerings may not be appropriate for all investors; readers should ensure they comprehend the associated risks and seek independent counsel if needed. Only invest funds you can afford to lose. Readers are strongly advised to conduct their own research and consult a qualified financial advisor before making any investment decisions. Neither the media platform nor the publisher will be held accountable for any fraudulent actions, misrepresentations, or financial losses stemming from this press release. We accept no liability or responsibility for any legal claims or charges related to this article. Globenewswire does not endorse any content on this page.
Legal Disclaimer: This media platform presents the article’s content “as-is,” without any express or implied warranties or representations. We disclaim responsibility for any inaccuracies, errors, or omissions. We are not liable for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information provided herein. Any concerns, complaints, or copyright issues pertaining to this article should be directed to the content provider identified above.
